Immix Biopharma said its Nexicart-2 trial of NXC-201 in relapsed/refractory AL amyloidosis reached an 89% complete response rate across all 45 patients, up from the 25-patient update in which all new patients were either in complete response or minimum residual disease-negative.
The company said 40 of 45 patients were in complete response at the interim readout, with the remaining five patients split between four who were already MRD-negative and one additional pending case. Immix said those four MRD-negative patients could lift the complete response rate to as high as 98%, or 44 of 45 patients, if they convert as expected.
Among the 25 newly added patients, 21 were already in complete response and 4 were MRD-negative. That means 100% of the new patients were either in complete response or MRD-negative at the time of the update.
Immix said every patient who achieved MRD-negativity had reached complete response within one year of treatment. The company also said it has seen no relapses to date among patients who reached complete response or MRD-negativity.
Safety data in the release showed no neurotoxicity and no enterocolitis observed to date.
The trial now stands at 45 patients, and Immix said final readout and BLA submission are planned for mid-2027. The market has reacted to these announcements by moving the company's shares 4.56% to a price of $11.47. For the full picture, make sure to review Immix Biopharma's 8-K report.
